Lexicon Pharmaceuticals, Inc. (LXRX)

Market Cap	519.66M
Revenue (ttm)	70.86M
Net Income (ttm)	-68.58M
Shares Out	363.40M
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	771,897
Open	1.410
Previous Close	1.410
Day's Range	1.390 - 1.440
52-Week Range	0.284 - 1.660
Beta	0.97
Analysts	Buy
Price Target	3.23 (+125.87%)
Earnings Date	Nov 6, 2025

About LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates u...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2000
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: LXRX
• Website: https://www.lexpharma.com

Financial Performance

In 2024, Lexicon Pharmaceuticals's revenue was $31.08 million, an increase of 2481.48% compared to the previous year's $1.20 million. Losses were -$200.40 million, 13.1% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for LXRX stock is "Buy." The 12-month stock price target is $3.23, which is an increase of 125.87% from the latest price.

Price Target

$3.23

(125.87% upside)

Analyst Consensus: Buy